04 Schillie mening 508

CDC ACIP — Vaccine Advisory Committee

Acip

Slides

6

Download PDF ↗ Live URL (may be dead)

Document text

Introduction to MenQuadfi Label Change for 
Infants
Sarah Schillie, MD, MPH, MBA
Advisory Committee on Immunization Practices
April 16, 2025National Center for Immunization & Respiratory Diseases
1
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position o f 
the U. S. Centers for Disease Control and Prevention.
MenACWY Vaccines Available for Use in the 
United States*
Manufacturer Trade Name AbbreviationLicensed 
Age GroupACIP 
Recommended 
Age Group*
Sanofi Pasteur Menactra MenACWY -D9 months –55 
years≥9 months
Sanofi Pasteur MenQuadfi MenACWY -TT ≥2 years ≥2 years
GlaxoSmithKline Menveo MenACWY -CRM2 months –55 
years≥2 months **
*Same product preferred, but not required, for all doses in a series
**Includes off -label recommendations for persons 56 years and older2 of 6
MenACWY Vaccine Recommendations*
Routinely recommended for persons at age 11–12 years and 
16 years
Recommended for persons aged ≥2 months with risk factors:
–Complement component deficiencies or complement inhibitor use
–Anatomic or functional asplenia
–HIV infection
–Microbiologists routinely exposed to N. meningitidis isolates 
–Persons at increased risk during an outbreak
–Persons who live in or travel to countries in which meningococcal disease is 
hyperendemic or epidemic 
*Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization 
Practices, United States, 2020. MMWR Recomm Rep 2020;69(No. RR -9):1– 41. DOI: http://dx.doi.org/10.15585/mmwr.rr6909a1 .
3 of 6
MenACWY Vaccine Recommendations
for Persons with Risk Factors*
<2 Years:
–Age 2 months:  4 -dose series (2, 4, 6, 12 mos)
–Age 3 –6 months:  3 - or 4- dose series (dose 2 [and dose 3 if applicable] ≥8 wks after 
previous dose until a dose is received at age ≥7 mos, followed by an additional dose 
≥12 wks later and at age >12 mos)
–Age 7 –23 months:  2- dose series (dose 2 ≥12 wks after dose 1 and at age >12 mos)
≥2 Years:  2 -dose primary series, with doses separated by 8 wks**
Booster dose:
–Age <7 years:  3 yrs after primary series and every 5 yrs thereafter 
–Age ≥7 years:  5 yrs after primary series and every 5 yrs thereafter
            *Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization 
Practices, United States, 2020. MMWR Recomm Rep 2020;69(No. RR -9):1– 41. DOI: http://dx.doi.org/10.15585/mmwr.rr6909a1 .
**Medical risk factors4 of 6
MenQuadfi Proposed Licensure in Infants
With discontinuation of Menactra, Menveo is the only 
MenACWY vaccine available in the United States for persons under 2 years of age
Sanofi Pasteur seeking infant indication for MenQuadfi for the following ages at initiation (anticipated May 2025):
–6 weeks –5 months:  2, 4, 6, 12– 18 months (first dose may be administered as 
early as 6 weeks) 
–6–23 months:  2- dose series with 2nd dose administered in second year of life 
and ≥3 months after 1st dose
–≥2 years:  1 dose
5 of 6
6Acknowledgements
Lucy McNamara
Avnika Amin
Amy Rubis
Susan Hariri
Noele Nelson
LeAnne Fox
Alison Albert
6 of 6